Lung Cancer Research Foundation Announces New Research Collaboration with Daiichi Sankyo and AstraZeneca
“NEW YORK, March 16, 2023 /PRNewswire/ — The Lung Cancer Research Foundation (LCRF) today announced a collaboration with Daiichi Sankyo and AstraZeneca to fund up to three research grants focused on antibody drug conjugates (ADCs) to improve outcomes for people with lung cancer. Applications for these grants are being accepted through May 31, 2023.”

Lung Cancer: How a Drug Combination May Help Reduce Tumors
“Lung cancer is the second most common type of cancer among adults in the United States, with almost a quarter of a million new diagnoses each year.”

Upfront Atezolizumab Poses Lower Risk of Hyperprogression in NSCLC
“The risk of hyperprogression is lower when atezolizumab is given upfront to patients with advanced non-small cell lung cancer (NSCLC), according to an analysis published in The Oncologist.”

IO/Chemo Associated With Higher Toxicity Risk in ES-SCLC
“In patients with extensive-stage small cell lung cancer (ES-SCLC), treatment with immunotherapy and chemotherapy was associated with a worse risk of toxicity and the likelihood of treatment discontinuation, according to results from a meta-analysis published in Thoracic Cancer.”

Outcomes in Extensive-Stage Small Cell Lung Cancer Based on Trial Eligibility
“A study in Japan involving patients with extensive-stage small cell lung cancer (ES-SCLC) indicated that pivotal clinical trial outcomes were comparable to those of patients receiving chemoimmunotherapy in the clinical practice setting. However, the study investigators also determined that clinical trial eligibility criteria may be relevant to outcomes. Results of this study were reported in JAMA Network Open.”

Updates in Targeted Therapies, Management Strategies for Non-Small Cell Lung Cancer
“Non-small cell lung cancer (NSCLC) is the leading cause of cancer related deaths in the United States. Most patients have advanced metastatic disease at diagnosis. Historically, platinum-based chemotherapy was the first-line therapy based on histologic subtype.”

Husain Discusses Role of Osimertinib in Non–Small Cell Lung Cancer
“During a Targeted Oncology™ Case-Based Roundtable™ event, Hatim Husain, MD, discussed data on targeted adjuvant therapy for non–small cell lung cancer.”

Double lung transplants successfully treat late-stage lung cancer, in a first with new technique
“(NEW YORK) — A new double lung transplant technique was successful for two patients with lung cancer, Northwestern Medicine announced. The hospital said it’s leveraging that success into a new clinical program that will offer transplants to patients with end-stage lung cancer.”

Study reveals ‘paradigm shift’ in non-small cell lung cancer during past decade
“A study of more than 20,000 patients with non-small cell lung cancer in Korea showed improvements in survival outcomes across all stages of disease between 2010 and 2020 amid increased use of molecular testing and targeted treatments.”

Another study finds increase in coal miner lung ailments
“CHARLESTON, W.Va. — A recent study by the University of Chicago found a trend upward of coal miners suffering higher incidents of black lung and of lung cancer.”